HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 9, 1997, Pages 1725-1729

  Hughes, Steven D ^a   Verstuyft, Judy ^a   Rubin, Edward M ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Apolipoprotein A I; Apolipoprotein B; Atherosclerosis; Genetics; Lipoproteins; Transgenic mice

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; FEMALE; GENETIC ENGINEERING; GENOTYPE; LIPOPROTEIN DEFICIENCY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030865194     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.9.1725     Document Type: Article

References (25)

1. Castelli WP, Garrison RJ, Wilson PWF, Abbott RF, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA. 19S6;256:2835-2842.
2. Gordon DJ, Knoke J, Probstfield JL, Superko R, Tryoler HA. High-density lipoprotein cholesterol and coronary heart disease in hypercholesterolemic men: the Lipid Research Clinics Coronary Primary Prevention Trial. Circulation. 1986;74:1217-1223.
3. Miller NE. Associations of high-density lipoprotein subclasses with ischemic heart disease and coronary atherosclerosis. Am Heart J. 1987;113:589-597.
4. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 1991;353:265-267.
5. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin ER. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 1993;365:762-765.
6. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein A-I transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest. 1994;94:899-903.
7. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high-density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1994;91:9607-9611.
8. Liu AC, Lawn RM, Verstuyft JG, Rubin EM. Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein(a) in transgenic mice. J Lipid Res. 1994;35:2263-2267.
9. Breslow J. Familial disorders of high-density lipoprotein metabolism. In: Seriver C, Beaudet A, Sly W, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill Publishing Co; 1995:1251-1266.
10. Ng DS, Vezina C, Wolever TS, Kuksis A, Hegele RA, Connelly PW. Apolipoprotein A-I deficiency: biochemical and metabolic characteristics. Arterioscler Thromb Vase Biol. 1995;15:2157-2164.
11. Williamson R, Lee D, Hagaman J, Maeda N. Marked reduction of high-density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci U S A. 1992;89:7134-7138.
12. Li H, Reddick RL, Maeda N. Lack of apo A-I is not associated with increased susceptibility to atherosclerosis in mice. Arterioscler Thromb. 1993;13:1814-1821.
13. Callow MJ, Verstuyft J, Tangirala R, Palinski W, Rubin EM. Atherogenesis in transgenic mice with human apolipoprotein(a), apolipoprotein B, and lipoprotein(a). J Clin Invest. 1995;96:1636-1646.
14. Purcell-Huynh DA, Farese RV Jr, Johnson DF, Flynn LM, Pierotti V, Newland DL, Linton MF, Sanan DA, Young SG. Transgenic mice expressing high levels of human apolipoprotein B develop severe atherosclerotic lesions in response to a high-fat diet. J Clin Invest. 1995;95:2246-2257.
15. Callow MJ, Stoltzfus LJ, Lawn RM, Rubin EM. Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. Proc Natl Acad Sci U S A. 1994;91:2130-2136.
16. Nishina PM, Verstuyft J, Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res. 1990;31:859-869.
17. Rubin EM, Ishida BY, Clift SM, Krauss RM. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high-density lipoprotein size subclasses. Proc Natl Acad Sci U S A. 1991;88:434-438.
18. Izzo C, Grillo F, Murador E. Improved method for determination of HDL cholesterol. Clin Chem. 1981;27:371-378.
19. Nichols AV, Krauss RM, Musliner TA. Nondenaturing polyacryl-amide gradient gel electrophoresis. In: Segrest JP, Albers JJ, eds. Methods in Enymology: Plasma Lipoproteins. New York, NY: Academic Press; 1986:417-431.
20. Blanche P, Callow M, Holl L, Rubin E, Krauss R. Similar low density lipoprotein subclasses in fat-fed human-apoB transgenic mice and humans. Circulation. 1995;92(suppl I):I-104. Abstract.
21. Paigen B, Holmes P, Mitchell D, Albee D. Comparison of atherosclerotic lesions and HDL-lipid levels in male, female, and testosterone-treated female mice from strains C57BL/6, BALB/c, and Cm. Atherosclerosis. 1987;64:215-221.
22. Glass CK, Pittman RC, Weinstein DB, Steinberg D. Dissociation of tissue uptake of cholesterol ester from that of apolipoprotein A-I of rat plasma high-density lipoprotein: selective delivery of cholesterol to liver, adrenal and gonad. Proc Natl Acad Sci U S A. 1983;80:5435-5439.
23. Pittman RC, Knecht TP, Rosenbaum MS, Taylor CA Jr. A nonendocytotic mechanism for the selective uptake of high-density lipoprotein associated cholesterol esters. J Biol Chem. 1987;262:2443-2450.
24. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high-density lipoprotein receptor. Science. 1996;271:518-520.
25. Plump AS, Erickson SK, Weng W, Partin JS, Breslow JL, Williams DL. Apolipoprotein A-I required for cholesteryl ester accumulation in steroidogenic cells and for normal adrenal steroid production. J Clin Invest. 1996;97:2660-2671.